A Study of ZG005 in Patients With Advanced Solid Tumors

Last updated: June 13, 2024
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Overall Status: Active - Recruiting

Phase

1/2

Condition

Neoplasms

Solid Tumors

Treatment

ZG005 Powder for Injection

Clinical Study ID

NCT06233292
ZG005-001
  • Ages 18-70
  • All Genders

Study Summary

This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Fully understand the study and voluntarily sign the informed consent form.

  • Male or female 18-70 years of age;

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;

  • Life expectancy ≥ 3 months;

  • Histologically or cytologically confirmed diagnosis of advanced solid tumors.

Exclusion

Exclusion Criteria:

  • Medical history, computed tomography (CT) or magnetic resonance imaging (MRI)results indicate that existence of the central nervous system(CNS) metastases;

  • Any other malignancy within 5 years.

Study Design

Total Participants: 484
Treatment Group(s): 1
Primary Treatment: ZG005 Powder for Injection
Phase: 1/2
Study Start date:
June 17, 2022
Estimated Completion Date:
January 31, 2026

Connect with a study center

  • Jilin Provincial Cancer Hospital

    Changchun, Jilin 130000
    China

    Site Not Available

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang 310022
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.